Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Assay
- Disease
- cardiac
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 203314
IPSCIO Record ID: 286069
Technology rights shall mean University rights in any technical information, know-how, processes, procedures, compositions, devices, methods, formulae, protocols, techniques, software, designs, drawings or data created by the inventors before the Effective Date relating to the use of liposomal vinca alkaloids which are not covered by patent rights but which are necessary for practicing the inventions covered patent rights.
The patents are for The Use of Liposomal Vincristine in Order to Circumvent Toxicity and Allow Administration of Higher Doses of Drug, and, Compositions and Methods for Treating Lymphoma.
IPSCIO Record ID: 289241
Licensor also grants a nonexclusive, worldwide, sublicensable license under Non-uPA Inhibitor Patents to carry out research and development in respect of uPA Inhibitor Compounds during the Research Program and to use any results of such research and development for the development, manufacture or commercialization of Licensed Compounds and Licensed Products.
Licensor also grants a nonexclusive, worldwide, sublicensable license under Improvements that are Controlled by Licensor during the term of this Agreement to research, develop, make, have made, use, sell and import for sale Licensed Products in the Field.
Urokinase Plasminogen Activator (uPA) Inhibitor means a compound that has uPA Ki as determinated by Licensor using a standardized assay reasonably acceptable to the Joint Research Committee less than 1.0 micromolar, and selectivity with respect to the Ki for the compound for uPA of at least 2X with respect to the Ki, as determined by Licensor using a standardized assay reasonably acceptable to the Joint Research Committee, for complement proteases; and selectivity with respect to the Ki for the compound for uPA of at least 10X with respect to the Ki, as determined by Licensor using a standardized assay reasonable acceptable to the Joint Research Committee, for Thrombin, Factor VIIa and Xa.
Licensor Technology means Licensor Know-How and Licensor Patents.
Licensed Compound means a Base Compound or a New Compound.
Licensed Product means a product in finished dosage form containing a Licensed Compound as active ingredient for use in the Field.
Base Compound' means a uPA Inhibitor existing at the Effective Date which falls within the claims of the Patents referenced or falls within the same Chemical Class as such compounds; or falls within Licensors orally available uPA Inhibitor lead series, exemplified by 5-bromo-4 (phenylamino) thiophene-2-carboxamidine hydrochloride and derivatives thereof, as described in the Outline Research Plan.
New Compound means any uPA Inhibitor and members of the same Chemical Class which is identified, discovered, created or synthesized by Licensor in the course of the Research Program; any chemical entity, and any member of the same Chemical Class as such chemical entity, that is identified, discovered, created or synthesized by Licensor and is discovered during the Research Term, but outside of the Research Program, to be a uPA Inhibitor, to the extent that such chemical entity is Controlled by Licensor; and any chemical entity, and any member of the same Chemical Class as such chemical entity that is identified, discovered, created or synthesized by Licensor and is discovered to be a uPA Inhibitor after the end of the Research Term but within 6 months thereafter, to the extent that such chemical entity is Controlled by Licensor.
Licensor Non-uPA Inhibitor Compounds mean compounds and data relating to such compounds discovered during the Research Program by Licensor which do not constitute uPA Inhibitors but which the Joint Research Committee considers have some biological activity of interest to the Research Program or are of potential commercial interest to Licensee.
Licensor Non-uPA Inhibitor Patents means Patents Controlled by Licensor which claim Non-uPA Inhibitor Compounds.
Licensor Patents means Heteroaryl Amidines, Methyl Amidines and Guanidines…; Patents to be filed by Licensor that claim Licensors orally available uPA Inhibitor lead series, and derivatives thereof, as described in the Outline Research Plan; and Patents that claim New Compounds.
IPSCIO Record ID: 240578
Licensed Subject Matter means inventions, discoveries, assays and processes covered by Patent Rights and/or Technology Rights within Licensed Field.
The patents are for Methods and Compositions Relating to Muscle Selective Calcineurin Interacting Protein (MCIP).
